Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis

In this report we estimated rates of monoclonal antibody (mAb) utilization, including bamlanivimab, casirivimab and/or imdevimab, and bamlanivimab and etesevimab, among authorized and unauthorized users, and examined counts of patients with Coronavirus Disease 2019 (COVID-19) in the Rapid COVID Sentinel Distributed Database (SDD).

• Group 1: The study period includes data from November 1, 2020 to June 22, 2021. We distributed this request to three Sentinel Data Partners on August 2, 2021.
• Group 2: The study period includes data from November 1, 2020 to June 30, 2021. We distributed this request to two Sentinel Data Partners on August 2, 2021.